The Foundation of Care: Medication and Lifestyle
At a Glance
For most people with stable coronary atherosclerosis, the foundation of care is individualized medication plus lifestyle change. Statins, appropriate antiplatelet therapy, exercise, a Mediterranean-style diet, smoking cessation, and control of blood pressure and diabetes help lower future heart risk.
While medical procedures like stents often get the most attention, the true foundation of living with coronary atherosclerosis is Guideline-Directed Medical Therapy (GDMT) and lifestyle modification. For most people with stable disease, these treatments are the most powerful tools available to prevent future heart attacks and extend life [1].
Important Safety Rule: Never start, stop, or substitute your aspirin, statins, beta-blockers, or antiplatelet medications without contacting your care team.
The Power of Medical Therapy
Research has shown that for patients with stable coronary disease, Optimal Medical Therapy (OMT) is incredibly effective. A landmark study called the ISCHEMIA trial followed over 5,000 patients with stable disease and moderate-to-severe ischemia, and found that those treated with intensive medication and lifestyle changes had similar rates of major heart events as those who received an initial invasive procedure [2][3].
However, it is important to know the trial’s limits: it excluded certain high-risk anatomies (such as unprotected left-main disease or recent acute coronary syndromes), and revascularization procedures still provide significant symptom relief and quality-of-life benefits for patients suffering from persistent angina. Modern medical therapy works by helping to stabilize the disease inside your arteries, making plaques less likely to rupture and cause a sudden blockage [4].
Core Medications
Your care team will tailor a combination of medications to address different aspects of the disease:
- High-Intensity Statins: These are the “workhorses” of CAD treatment. High-intensity versions (like atorvastatin or rosuvastatin) are proven to lower LDL (“bad”) cholesterol significantly and reduce the risk of recurrent events [5].
- Targeting LDL: Your clinician will individualize your LDL goal based on guidelines and your risk. While U.S. guidelines often use a threshold of 70 mg/dL to add therapy, European and some very-high-risk guidelines aim for an LDL-C target of below 55 mg/dL [6]. If statins alone don’t reach this goal or if you have side effects, your doctor may add non-statin therapies like ezetimibe [7].
- Antiplatelet Therapy: Antiplatelets prevent blood clots. For established clinical coronary disease or secondary prevention, low-dose aspirin (81 mg) is routinely used [8]. However, aspirin is not appropriate for everyone. The clinician must individualize this choice based on your bleeding risk, age, and whether the plaque was just an incidental finding on a scan. If you cannot take aspirin, clopidogrel may be used as an alternative, but it must be explicitly prescribed by your doctor [9].
- Beta-Blockers: These medications lower your heart rate and blood pressure, reducing the workload on your heart [10]. They are especially important if you have had a prior heart attack or have heart failure, though your doctor may individualize their long-term use [11][12].
Essential Lifestyle Changes
Medication works best when paired with aggressive lifestyle changes. Think of these not as “suggestions,” but as active treatments for your disease.
- The Mediterranean Diet: This eating pattern—rich in fruits, vegetables, whole grains, beans, and healthy fats like olive oil—is strongly recommended for heart health [1]. It focuses on reducing processed meats and refined sugars.
- Cardiac Rehabilitation: This is a formal, supervised program that includes exercise training, education on heart-healthy living, and counseling [1]. Patients who participate often have better long-term outcomes.
- Smoking Cessation: Quitting smoking or vaping is perhaps the single most impactful change you can make [1]. Tobacco use accelerates plaque growth.
- Blood Pressure and Diabetes Management: Your clinician will set individualized targets. While common starting goals are keeping blood pressure below 130/80 mmHg and HbA1c below 7%, these may be relaxed or intensified based on your age, frailty, kidney disease, or hypoglycemia risk [13][14].
By committing to this “medical foundation,” you aren’t just managing symptoms—you are actively changing the biology of your disease and protecting your heart for the years to come. If you have concerns about cost or side effects, discuss practical options with your care team.
Common questions in this guide
What is the main treatment for stable coronary atherosclerosis?
What LDL cholesterol goal should I have with coronary atherosclerosis?
Do I need aspirin for coronary atherosclerosis?
Can lifestyle changes really help treat coronary atherosclerosis?
Is cardiac rehabilitation useful for people with coronary atherosclerosis?
Can medication work as well as a stent for stable coronary disease?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my risk factors, what is my clinician-set target LDL cholesterol number?
- 2.If my LDL doesn't reach our target on a statin, would a non-statin medication like ezetimibe be the right next step for me?
- 3.Am I a good candidate for cardiac rehabilitation to help me start a safe and effective exercise program?
- 4.How does my specific anatomy or history influence the results of the ISCHEMIA trial as it applies to me?
- 5.Do I need to be on an antiplatelet medication, and do my bleeding risks outweigh the benefits?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.
, Virani SS, Newby LK, et al.
Journal of the American College of Cardiology 2023; (82(9)):833-955 doi:10.1016/j.jacc.2023.04.003.
PMID: 37480922 - 2
ISCHEMIA trial: Is there enough evidence to drive a change in clinical practice? A critical appraisal.
Tziakas D, Chalikias G, Triantis G, Dagre A
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2020; (61(3)):204-207 doi:10.1016/j.hjc.2020.08.006.
PMID: 32916291 - 3
Screening for participants in the ISCHEMIA trial: Implications for clinical research.
Rodriguez F, Hochman JS, Xu Y, et al.
Journal of clinical and translational science 2022; (6(1)):e90 doi:10.1017/cts.2022.428.
PMID: 36003207 - 4
Statin non-adherence: clinical consequences and proposed solutions.
Rosenson RS
F1000Research 2016; (5()).
PMID: 27134737 - 5
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Roe MT, Li QH, Bhatt DL, et al.
Circulation 2019; (140(19)):1578-1589 doi:10.1161/CIRCULATIONAHA.119.042551.
PMID: 31475572 - 6
Clinical impact of ≥50% reduction of low density lipoprotein cholesterol following lipid lowering therapy on cardiovascular outcomes in patients with acute coronary syndrome.
Fujioka S, Shishikura D, Kusumoto H, et al.
Journal of clinical lipidology 2025; (19(2)):247-255 doi:10.1016/j.jacl.2024.10.010.
PMID: 40024838 - 7
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP, Blazing MA, Giugliano RP, et al.
The New England journal of medicine 2015; (372(25)):2387-97 doi:10.1056/NEJMoa1410489.
PMID: 26039521 - 8
Why low-dose aspirin remains an important antiplatelet in the management of chronic coronary syndromes.
Sibbing D, Lavalle Cobo AM, Shi Z, et al.
Expert review of cardiovascular therapy 2025; (23(5)):187-195 doi:10.1080/14779072.2025.2505439.
PMID: 40357728 - 9
P2Y12 Inhibitor or Aspirin Monotherapy for Chronic Coronary Disease: A Nationwide Cohort Study.
Baik M, Jeon J, Yoo J, Kim J
Cardiovascular therapeutics 2025; (2025()):2715470 doi:10.1155/cdr/2715470.
PMID: 41438591 - 10
The clinical value of β-blockers in patients with stable angina.
Palatini P, Faria-Neto JR, Santos RD
Current medical research and opinion 2024; (40(sup1)):33-41 doi:10.1080/03007995.2024.2317443.
PMID: 38597064 - 11
Effects of β-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease.
Tsujimoto T, Sugiyama T, Kajio H
Diabetes, obesity & metabolism 2017; (19(6)):800-808 doi:10.1111/dom.12878.
PMID: 28094466 - 12
Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis.
Chi KY, Lee PL, Chowdhury I, et al.
European journal of preventive cardiology 2025; (32(8)):633-646 doi:10.1093/eurjpc/zwae298.
PMID: 39298680 - 13
Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial.
Newman JD, Alexander KP, Gu X, et al.
Circulation. Cardiovascular quality and outcomes 2019; (12(11)):e006002 doi:10.1161/CIRCOUTCOMES.119.006002.
PMID: 31718297 - 14
Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes.
Mancini GBJ, Maron DJ, Hartigan PM, et al.
Journal of the American College of Cardiology 2019; (73(16)):2049-2058 doi:10.1016/j.jacc.2018.11.067.
PMID: 31023428
This page explains medication and lifestyle treatment for coronary atherosclerosis for educational purposes, not as individualized medical advice. Do not start, stop, or change aspirin, statins, beta-blockers, or other antiplatelet medicines without speaking with your care team.
Get notified when new evidence is published on coronary atherosclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.